Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice.
Overview
and 8 other authors
Ran He1,3, Yijie Ma6, Jun Yang6, Heather L. Gray-Edwards1,2, Thomas L. Gallagher1, Phillip W. L. Tai1,2,4, Guangping Gao1,2,4, Jun Xie1,3,4- Horae Gene Therapy Center, Department of Genetic and Cellular Medicine, UMass Chan Medical School,Worcester, MA USA
- Li Weibo Institute for Rare Diseases Research, UMass Chan Medical School,Worcester, MA USA
- Viral Vector Core, UMass Chan Medical School,Worcester, MA USA
- Department of Microbiology, UMass Chan Medical School,Worcester, MA USA
- Division of Cardiovascular Medicine, Department of Medicine, UMass Chan Medical School,Worcester, MA USA
- CANbridge Pharmaceuticals, Burlington, MA USA
Abstract
Spinal muscular atrophy (SMA) results from a deficiency of the survival motor neuron (SMN) protein. Zolgensma, an adeno-associated virus (AAV)-based SMN1 gene-replacement therapy, is approved for SMA, though its long-term efficacy and safety remain uncertain. This study compares a Zolgensma-like benchmark vector with a 2nd-generation vector featuring a codon-optimized SMN1 transgene under the control of an endogenous SMN1 promoter. In SMA mice, intracerebroventricular delivery of the 2nd-generation vector improved survival and phenotypic outcomes compared with the benchmark. However, motor impairment was observed in wild-type mice 20 months post-injection with the 2nd-generation vector. Notably, cardiac thrombosis and hepatocellular carcinoma were associated with the benchmark vector, but not with the 2nd-generation vector. While AAV-related tumorigenesis appears to be species-specific to mice, these findings underscore the need for careful long‑term monitoring in patients treated with Zolgensma.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- bioproject:PRJNA1365939, at NCBI BioProject; found in “Data availability”
Data availability
The gene expression data reported here have been deposited in the NCBI Sequence Read Archive (SRA) under the accession number: PRJNA1365939 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 28 authors, 2 keywords, 18 MeSH terms, 1 funder, 97 references.
Cite
This paper
Chen, X., Xie, Q., Nath, S. J., Tang, M., Ma, H., Günes, Y. Ö., Sharma, T., Liu, H., Cui, M., Du, A., Lu, M., Liu, S. Y., Wassamon, B., Xu, M., Wu, J. Y., Su, Q., Fitzgibbons, T. P., Liu, J., Wan, F., . . . Xie, J. (2026). Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice. Nature communications, 17(1), 6767. https://
BibTeX
@article{chen2026long,
author = {Chen, Xiupeng and Xie, Qing and Nath, Sarah J. and Tang, Mojiao and Ma, Hong and Günes, Yasemin Özgür and Sharma, Tapan and Liu, Hao and Cui, Mengtian and Du, Ailing and Lu, Mengjia and Liu, Sophia Y. and Wassamon, Boonying and Xu, Mengyao and Wu, Joseph Yunxi and Su, Qin and Fitzgibbons, Timothy P. and Liu, Jinghua and Wan, Fang and Kumanan, Veena and He, Ran and Ma, Yijie and Yang, Jun and Gray-Edwards, Heather L. and Gallagher, Thomas L. and Tai, Phillip W. L. and Gao, Guangping and Xie, Jun},
title = {{Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice}},
journal = {Nature communications},
year = {2026},
month = may,
volume = {17},
number = {1},
pages = {6767},
publisher = {Nature Publishing Group},
issn = {2041-1723},
doi = {10.1038/
url = {https://
pmid = {42177183},
pmcid = {PMC13385853}
}
RIS
TY - JOUR
AU - Chen, Xiupeng
AU - Xie, Qing
AU - Nath, Sarah J.
AU - Tang, Mojiao
AU - Ma, Hong
AU - Günes, Yasemin Özgür
AU - Sharma, Tapan
AU - Liu, Hao
AU - Cui, Mengtian
AU - Du, Ailing
AU - Lu, Mengjia
AU - Liu, Sophia Y.
AU - Wassamon, Boonying
AU - Xu, Mengyao
AU - Wu, Joseph Yunxi
AU - Su, Qin
AU - Fitzgibbons, Timothy P.
AU - Liu, Jinghua
AU - Wan, Fang
AU - Kumanan, Veena
AU - He, Ran
AU - Ma, Yijie
AU - Yang, Jun
AU - Gray-Edwards, Heather L.
AU - Gallagher, Thomas L.
AU - Tai, Phillip W. L.
AU - Gao, Guangping
AU - Xie, Jun
TI - Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice
T2 - Nature communications
J2 - Nat Commun
PY - 2026
DA - 2026/
VL - 17
IS - 1
SP - 6767
SN - 2041-1723
PB - Nature Publishing Group
DO - 10.1038/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1038/
"type": "article-journal",
"title": "Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice",
"container-title": "Nature communications",
"author": [
{
"family": "Chen",
"given": "Xiupeng"
},
{
"family": "Xie",
"given": "Qing"
},
{
"family": "Nath",
"given": "Sarah J."
},
{
"family": "Tang",
"given": "Mojiao"
},
{
"family": "Ma",
"given": "Hong"
},
{
"family": "Günes",
"given": "Yasemin Özgür"
},
{
"family": "Sharma",
"given": "Tapan"
},
{
"family": "Liu",
"given": "Hao"
},
{
"family": "Cui",
"given": "Mengtian"
},
{
"family": "Du",
"given": "Ailing"
},
{
"family": "Lu",
"given": "Mengjia"
},
{
"family": "Liu",
"given": "Sophia Y."
},
{
"family": "Wassamon",
"given": "Boonying"
},
{
"family": "Xu",
"given": "Mengyao"
},
{
"family": "Wu",
"given": "Joseph Yunxi"
},
{
"family": "Su",
"given": "Qin"
},
{
"family": "Fitzgibbons",
"given": "Timothy P."
},
{
"family": "Liu",
"given": "Jinghua"
},
{
"family": "Wan",
"given": "Fang"
},
{
"family": "Kumanan",
"given": "Veena"
},
{
"family": "He",
"given": "Ran"
},
{
"family": "Ma",
"given": "Yijie"
},
{
"family": "Yang",
"given": "Jun"
},
{
"family": "Gray-Edwards",
"given": "Heather L."
},
{
"family": "Gallagher",
"given": "Thomas L."
},
{
"family": "Tai",
"given": "Phillip W. L."
},
{
"family": "Gao",
"given": "Guangping"
},
{
"family": "Xie",
"given": "Jun"
}
],
"container-title-short":
"volume": "17",
"issue": "1",
"page": "6767",
"DOI": "10.1038/
"PMID": "42177183",
"PMCID": "PMC13385853",
"ISSN": "2041-1723",
"publisher": "Nature Publishing Group",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
23
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1126/science.adg6518 [code]
- Base editing rescue of spinal muscular atrophy in cells and in mice.Journal: Science (New York, N.Y.)In common: other condition, mouse, 11 references, 2 authors
- [2] doi:10.1038/s44321-025-00303-6
- Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy.Journal: EMBO molecular medicineIn common: other condition, mouse, 12 references
- [3] doi:10.1002/1873-3468.70303
- Organ-specific redox imbalances in spinal muscular atrophy mice are partially rescued by SMN antisense oligonucleotides.Journal: FEBS lettersIn common: other condition, mouse, 9 references
- [4] doi:10.1016/j.omta.2026.201757
- Extracellular vesicles as biomarkers of disease progression and therapeutic response in patients with spinal muscular atrophy.Journal: Molecular therapy. AdvancesIn common: other condition, 9 references
- [5] doi:10.1016/j.xcrm.2024.101659 [code]
- Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation.Journal: Cell reports. MedicineIn common: other condition, mouse, 8 references
- [6] doi:10.1016/j.celrep.2024.115147
- Catecholaminergic dysfunction drives postural and locomotor deficits in a mouse model of spinal muscular atrophy.Journal: Cell reportsIn common: other condition, mouse, 7 references
- [7] doi:10.1172/jci.insight.158380
- Bap1/
SMN axis in Dpp4+ skeletal muscle mesenchymal cells regulates the neuromuscular system. Journal: JCI insightIn common: mouse, 7 references - [8] doi:10.1186/s10020-025-01207-4
- Preclinical evaluation of AAV9-coSMN1 gene therapy for spinal muscular atrophy: efficacy and safety in mouse models and non-human primates.Journal: Molecular medicine (Cambridge, Mass.)In common: other condition, mouse, 6 references
- [9] doi:10.1016/j.omtm.2025.101599
- Systemic mRNA-LNP administration in fetuses improves survival in a mouse model of spinal muscular atrophy.Journal: Molecular therapy. Methods & clinical developmentIn common: other condition, mouse, 6 references
- [10] doi:10.1016/j.omtm.2024.101300
- Treating late-onset Tay Sachs disease: Brain delivery with a dual trojan horse protein.Journal: Molecular therapy. Methods & clinical developmentIn common: mouse, 6 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
